SCHEMBL533347

SCHEMBL533347

ClC(Cl)Oc1nc(-c2cc[c]cc2)cs1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.34
CYP3A4 P08684 1/20 0.34
LTA4H P09960 3/20 0.33
RAB9A P51151 7/20 0.32
NPC1 O15118 5/20 0.32
SMN1; SMN2 Q16637 4/20 0.32
MAPT P10636 3/20 0.32
POLB P06746 1/20 0.32
KDM4E B2RXH2 2/20 0.31
LMNA P02545 2/20 0.31
GAA P10253 1/20 0.31
MEN1 O00255 1/20 0.31
NFKB1 P19838 1/20 0.31
NFKB2 Q00653 1/20 0.31
KMT2A Q03164 1/20 0.31
RELA Q04206 1/20 0.31
MKNK1 Q9BUB5 1/20 0.31
MKNK2 Q9HBH9 1/20 0.31
ALOX5 P09917 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL533598 0.84 RAB9A (0.35) ALDH1A1CYP3A4LTA4HRAB9ANPC1
SCHEMBL533303 0.84 ALDH1A1 (0.34) ALDH1A1CYP3A4LTA4HRAB9ANPC1
SCHEMBL533701 0.78 MAPT (0.45) ALDH1A1CYP3A4LTA4HRAB9ANPC1
SCHEMBL533569 0.77 ALDH1A1 (0.34) ALDH1A1CYP3A4LTA4HRAB9ANPC1
SCHEMBL533579 0.75 ALDH1A1 (0.37) ALDH1A1CYP3A4LTA4HRAB9ANPC1
SCHEMBL532989 0.74 RAB9A (0.35) ALDH1A1CYP3A4LTA4HRAB9ANPC1
SCHEMBL533127 0.74 ALOX5 (0.39) ALDH1A1CYP3A4LTA4HRAB9ANPC1
SCHEMBL534215 0.74 ALOX5 (0.39) ALDH1A1CYP3A4RAB9ANPC1SMN1; SMN2
SCHEMBL533529 0.72 MAPT (0.46) RAB9ANPC1SMN1; SMN2MAPTLMNA
SCHEMBL534232 0.72 CYP19A1 (0.41) ALDH1A1CYP3A4LTA4HRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2415763-B1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA UBE INDUSTRIES (JP) 2016-01-27 EP disclosed
US-20140113907-A1 PYRIDYLAMINOACETIC ACID COMPOUND UBE INDUSTRIES, LTD. (JP) 2014-04-24 US disclosed
US-8648097-B2 Pyridylaminoacetic acid compound UBE INDUSTRIES, LTD. (JP) 2014-02-11 US disclosed
US-20120190852-A1 MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA UBE INDUSTRIES, LTD. (JP) 2012-07-26 US disclosed
CN-102448940-A Pharmaceutical composition for treating or preventing glaucoma UBE INDUSTRIES 2012-05-09 CN disclosed
EP-2415763-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA Ube Industries, Ltd. (JP) 2012-02-08 EP disclosed
US-20110054172-A1 PYRIDYLAMINOACETIC ACID COMPOUND UBE CORPORATION (JP) 2011-03-03 US disclosed
EP-2264009-A1 PYRIDYLAMINOACETIC ACID COMPOUND Ube Industries, Ltd. (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140113907-A1 PYRIDYLAMINOACETIC ACID COMPOUND PTGER2, PTGER1, PTGDR2 ALDH1A1 204/4885CYP3A4 1198/4885LTA4H 37/4885
US-20110054172-A1 PYRIDYLAMINOACETIC ACID COMPOUND PTGER2, PTGER1, PTGDR2 ALDH1A1 256/4885CYP3A4 1337/4885LTA4H 32/4885
US-20120190852-A1 MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA F12, C1S, AKR1C3 ALDH1A1 377/4885CYP3A4 936/4885LTA4H 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.